期刊文献+

乳腺癌分子靶向治疗与生物化疗 被引量:7

The molecular target therapy and biochemotherapy for the breast cancer
下载PDF
导出
摘要 乳腺癌的治疗 ,继手术、放疗和化疗三大传统模式之后 ,生物治疗已被公认为治疗恶性肿瘤的第四大模式 ;分子靶向治疗药物的出现和在临床的广泛应用 ,使得生物治疗在肿瘤的综合治疗中发挥了日渐重要的作用。生物治疗与化疗的结合 ,提出了恶性肿瘤的治疗的新概念 -生物化疗的概念。 Except for surgery,raidiotherapy and chemotherapy,biotherapy has been the fourth mode of the therapy for the breast cancer,which has been more and more important in the integrative therapy since 'herceptin',a humanized mouse monoclonal antibody directed against the extracellular domain of the Her-2/neu protein,beening widely used in clinic.Since then on,the scientists have brought out a new conception,called 'biochemotherapy'.
出处 《癌症进展》 2004年第5期370-373,共4页 Oncology Progress
关键词 生物化疗 靶向治疗 乳腺癌 biochemotherapy target therapy breast cancer
  • 相关文献

参考文献15

  • 1[1]Slamon DJ, Godophin W, Jones LA, et al. Studies of the Her -2/neu proto - oncogene in human breast and ovarian cancer.Science, 1989, 244:707
  • 2[2]Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand- receptor interactionsFEBS Lett, 1997, 410:83
  • 3宋海珠.Herceptin治疗转移性乳腺癌的研究进展[J].中国肿瘤生物治疗杂志,2002,9(2):144-145. 被引量:14
  • 4[4]Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her - 2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridixationJ. Clin Pathol, 2000, 53:374
  • 5[5]Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her- 2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization Mod Pathol, 2000, 13:37
  • 6[6]Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti - Her - 2 monoclonal antibody in women who have Her - 2 - overexpressing metastatic breast cancer that has progressed after chmotherapy for metastatic diseaseJ. ClinOncol, 1999, 17:2639
  • 7[7]Seidman AD, Fornier M, Estiva F, et al. Final report: Weekly Herceptin and Taxol for meatstatic breast cancer: Analysis of efficacy by Her- 2 immunophnotype immunohistochemistry (IHC) and gene amplification fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol, 2000, 19:319
  • 8[8]Shak S. For the Herceptin Multinational Investigator Study Group.Overview of the trastuzumab (Herceptin) anti- Her- 2 monoclonal antibody clinical program in Her- 2- overexpressing metastatic breast cancer. Semin Oncol, 1999, 26 (Suppl 12) :71
  • 9罗荣城,季晨阳,李爱民,尤长宣,张军一,石敏,缪景霞,宋海珠.Herceptin治疗Her-2过度表达的转移性乳腺癌7例报告[J].解放军医学杂志,2002,27(10):911-912. 被引量:5
  • 10罗荣城,李爱民,张军一,廖旺军,季晨阳,缪景霞.Herceptin治疗Her-2过度表达的转移性乳腺癌[J].中华肿瘤杂志,2004,26(1):52-54. 被引量:17

二级参考文献8

  • 1孙燕.乳腺癌的内科治疗现代诊断与治疗[M].北京:北京医科大学和中国协和医科大学联合出版社,1988,9.193-196.
  • 2Baselga J, Tripathy D, Mendelsohn J, et al, Phase II study of weekly intravenous recombiTmnt humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. JClin Oncol, 1996, 14: 737-744.
  • 3Vogel CL, Cobleigh MA, Tripalhy D, et al. First-line herceptin monolherapy in metastatic breast cancer. Oncology 2001,61 ( Suppl2).37-42.
  • 4Fomier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin-Oncol,2000, 27: 38-45.
  • 5Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 1998, 58: 2825-2831.
  • 6周爱萍,冯奉仪.乳腺癌靶向治疗:Herceptin的研究进展[J].国外医学(肿瘤学分册),2000,27(3):167-170. 被引量:18
  • 7夏梦.Herceptin治疗妇科恶性肿瘤的机制及应用前景[J].国外医学(妇产科学分册),2000,27(4):206-209. 被引量:3
  • 8宋海珠.Herceptin治疗转移性乳腺癌的研究进展[J].中国肿瘤生物治疗杂志,2002,9(2):144-145. 被引量:14

共引文献31

同被引文献58

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部